NCT03647111View on ClinicalTrials.gov

Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer

RecruitingOBSERVATIONAL

Enrollment

120

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

December 31, 2024

Study Completion Date

December 1, 2025

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Crizotinib

Crizotinib 250mg po bid

Trial Locations (1)

410013

RECRUITING

Hunan Cancer Hospital, Changsha

All Listed Sponsors

lead

Hunan Province Tumor Hospital

OTHER